### ORBENIN-DC- cloxacillin benzathine suspension Merck Sharp & Dohme Corp.

-----

Orbenin-DC™ (cloxacillin benzathine intramammary infusion)

**CAUTION:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

**DESCRIPTION:** Orbenin-DC (cloxacillin benzathine intramammary infusion) is a stable, nonirritating suspension of cloxacillin benzathine containing the equivalent of 500 mg of cloxacillin per disposable syringe. Orbenin-DC is manufactured by a nonsterilizing process.

Cloxacillin benzathine is a semisynthetic penicillin derived from the penicillin nucleus, 6-amino-penicillanic acid. Cloxacillin benzathine is the benzathine salt of 6-[3-(2-chlorophenyl)-5-methylisoxazolyl-4-carboxamido] penicillanic acid.

The low solubility of Orbenin-DC results in an extended period of activity. Therefore, directions for use should be followed explicitly.

**ACTION:** Cloxacillin benzathine is bactericidal in action against susceptible organisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell wall mucopeptide. It is active against gram-positive organisms associated with mastitis such as *Staphylococcus aureus* and *Streptococcus agalactiae* and, because of its resistance to penicillinase, penicillin G-resistant staphylococci which may be the cause of mastitis.

Appropriate laboratory tests should be conducted, including in vitro culturing and susceptibility tests on pretreatment milk samples collected aseptically.

**SUSCEPTIBILITY TEST:** The Kirby-Bauer<sup>1</sup> procedure, utilizing antibiotic susceptibility disks, is a quantitative method that may be adapted to determining the sensitivity of bacteria in milk to Orbenin-DC.

For testing the effectiveness of Orbenin-DC in milk, follow the Kirby-Bauer procedure using the 1 mcg oxacillin susceptibility disk. Zone diameters for interpreting susceptibility are:

Resistant	Intermediate	Susceptible
≤ 10 mm	11-12 mm	≥ 13 mm

<sup>1</sup> Bauer AW, Kirby WMM, Sherris JC, et al: Antibiotic testing by a standardized single disk method, *Am J Clin Path* 45:493, 1966. Standardized Disk Susceptibility Test, *Federal Register* 37:20527–29, 1972.

**INDICATIONS:** Orbenin-DC is indicated in the treatment and prophylaxis of bovine mastitis in nonlactating cows due to *Staphylococcus aureus* and *Streptococcus agalactiae*.

CONTRAINDICATIONS: Because cloxacillin benzathine is relatively insoluble, Orbenin-

DC's activity will be prolonged. Therefore, Orbenin-DC should not be used for the occasional cow which may have a dry period of less than 4 weeks. This precaution will avoid residues in the milk following removal of the colostrum.

**WARNINGS:** For use in dry cows only. Do not use within 4 weeks (28 days) of calving. Treated animals must not be slaughtered for food purposes within 4 weeks (28 days) of treatment.

**PRECAUTION:** Because it is a derivative of 6-amino-penicillanic acid, Orbenin-DC has the potential for producing allergic reactions. Such reactions are rare; however, should they occur, the subject should be treated with the usual agents (antihistamines, pressor amines).

**DOSAGE AND ADMINISTRATION:** At the last milking of lactation, milk the cow out normally. Clean and disinfect the teats with alcohol swabs provided in the pail and infuse 1 syringe of Orbenin-DC, which has been warmed to room temperature, into each quarter. Do not milk out. The cow may be milked as usual when she calves.

The extent of subclinical and latent mastitis in a herd is frequently greater than suspected. In untreated herds a significant buildup of subclinical mastitis may occur during the dry period, which results in clinical severity after a few lactations. The adverse influence of subclinical mastitis on milk yield, the risk of cross-infection, and the chance of clinical mastitis flare-up make it necessary to treat the matter as a herd problem. Clinical studies have proven the value of treating all the cows in heavily infected herds as they are dried off. When the herd infection has been reduced, it may be desirable to be more selective in treating infected quarters.

Each pail contains 144 alcohol wipes to facilitate proper cleaning and disinfecting of the teat orifice.

**HOW SUPPLIED:** Orbenin-DC is supplied in pails of 144 single dose syringes with 144 alcohol wipes. Each disposable syringe contains 500 mg of cloxacillin as the benzathine salt in 7.5 g of suitable base.

#### Do Not Store Above 24°C (75°F)

Orbenin-DC<sup>™</sup> is a trademark used by Intervet Inc.

Approved by FDA under NADA # 055-069

TAKE TIME



Manufactured by: G.C. Hanford Mfg. Co. Syracuse, NY 13201

© 2015-2021 Intervet Inc., a subsidiary of Merck & Co., Inc., Madison, NJ 07940, US All rights reserved.

Rev. 08/2021

359106 R3 PAL16270 01

**MERCK** 

#### PRINCIPAL DISPLAY PANEL - 7.5 g Syringe Label

Orbenin-DC™ (cloxacillin benzathine intramammary infusion) 7.5 g

**DRY COW** 

Long Acting Formula

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Approved by FDA under NADA # 055-069.



#### PRINCIPAL DISPLAY PANEL - 7.5 g Syringe Carton

Orbenin-DC™ (cloxacillin benzathine intramammary infusion)

**DRY COW** 

#### Intramammary Infusion

short tip

#### LONG-ACTING FORMULA

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

12 single-dose (7.5 g), disposable syringes

Approved by FDA under NADA # 055-069

MERCK Animal Health



## Orbenin-DC™ (cloxacillin benzathine intramammary infusion)

#### **DRY COW** (VACA SECA)

Intramammary Infusion (Infusión intramamaria)

LONG-ACTING FORMULA (FÓRMULA DE LARGA ACCIÓN)


READ RESIDUE WARNING





#### Do not print Lot and Exp will be embossed in this area

səgninya əldəsoqaib ,(g.č.f.) əsob-əlgnis Sf (snamementa noizutal) noisulal yremmementil (FO RMU LA DE LARG A ACCION) LONG- ACTING FOR MULA



intramamery infusion) (cloxacillin benzathine





intramammary infusion) DRY COW (VACA SECA)


Description: Each single-dose, disposable syringe contains cloxacillin benzathine equivalent to 500 mg of cloxacillin in 7.5 g of a suitable base. Orbenin-DC is manufactured by a nonsterilizing process.

Indications: For the treatment and prophylaxis of bovine mastitis in non-lactating cows due to Staphylococcus aureus and Streptococcus agalactiae.

Dosage and Administration: At the last milking of lactation, milk the cow out normally. Clean and disinfect the teats with alcohol swabs provided in the carton, and infuse 1 syringe of Orbenin-DC, which has been warmed to room temperature, into each quarter. Do not milk out. The cow may be milked as usual when she calves.



Warnings: For use in dry cows only. Do not use within 4 weeks (28 days) of calving. Treated animals must not be slaughtered for food purposes within 4 weeks (28 days) of treatment.



Veterinary Use Only—Not for Human Use Keep Out of Reach of Children Discard Empty Container-Do Not Reuse Do Not Store Above 24°C (75°F) **Read Insert for Complete Directions** 

Manufactured by: G.C. Hanford Mfg. Co. Syracuse, NY 13201

Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. Rev. 10/2022

CTN15481 05





### Orbenin-DC (cloxacillin benzathine

intramammary infusion)

**DRY COW** (VACA SECA)

Intramammary Infusion (Infusión intramamaria)


LONG-ACTING FORMULA (FÓRMULA DE LARGA ACCIÓN)

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

12 single-dose (7.5 g), disposable syringes







#### **ORBENIN-DC**

cloxacillin benzathine suspension

#### **Product Information**

Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:0061-8134

**Route of Administration** INTRAMAMMARY

# Active Ingredient/Active Moiety Ingredient Name Basis of Strength Cloxacillin benzathine (UNII: AC79L7PV2G) (cloxacillin - UNII: O6X5QGC2VB) Strength Cloxacillin cloxacillin 500 mg in 7.5 mL

P	Packaging						
#	Item Code	Package Description	<b>Marketing Start Date</b>	Marketing End Date			
1	NDC:0061-8134-01	12 in 1 CARTON					
1		7.5 mL in 1 SYRINGE					
2	NDC:0061-8134-06	144 in 1 PAIL					
2		7.5 mL in 1 SYRINGE					

Marketing Information						
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date			
NADA	NADA055069	03/11/1975				

Merck Sharp & Dohme Corp.